Departamento académico
(FM) Oncología
Argitalpenak (79) Ikertzaileren baten partaidetza izan duten argitalpenak
2024
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future Oncology, Vol. 20, Núm. 13, pp. 799-809
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583
-
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis
Clinical and Translational Oncology
-
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer
Molecular Cancer, Vol. 23, Núm. 1
-
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)
International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945
-
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)
Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186
-
Antibody-drug conjugate targeting folate receptor α: a new milestone in personalized medicine for high-grade serous ovarian cancer
International Journal of Gynecological Cancer
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738
-
Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers
British Journal of Surgery, Vol. 111, Núm. 3
-
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
European Journal of Cancer, Vol. 202
-
Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy
Radiotherapy and Oncology, Vol. 198
-
Current Challenges for Conscientious Objection by Physicians in Spain
Linacre Quarterly
-
Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer
Seminars in Oncology Nursing, Vol. 40, Núm. 1
-
Current landscape of gastrointestinal radiation oncology in Spain: a multicenter real-life survey and comparison with key clinical guidelines
Reports of Practical Oncology and Radiotherapy, Vol. 29, Núm. 3, pp. 340-347
-
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming
Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151
-
Dendritic Cells in Cancer Immunology and Immunotherapy
Cancers, Vol. 16, Núm. 5
-
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study
Clinical Genitourinary Cancer, Vol. 22, Núm. 5
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266